Volume 3, Issue 1 (Winter 2017)                   Caspian.J.Neurol.Sci 2017, 3(1): 46-53 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Lyman D. B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease . Caspian.J.Neurol.Sci. 2017; 3 (1) :46-53
URL: http://cjns.gums.ac.ir/article-1-154-en.html
MPH retired, Department of Family Medicine, University of Tennessee, Jackson, Tennessee; dlymanmdmph@gmail.com
Abstract:   (1843 Views)

The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells.

Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells.

The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies.

Full-Text [PDF 761 kb]   (1350 Downloads) |   |   Full-Text (HTML)  (4178 Views)  
Type of Study: Review | Subject: Special
Received: 2017/04/13 | Accepted: 2017/04/13 | Published: 2017/04/13

Add your comments about this article : Your username or Email:

© 2017 All Rights Reserved | Caspian Journal of Neurological Sciences

Designed & Developed by : Yektaweb